Veeva Systems Inc
NYSE:VEEV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (54.6), the stock would be worth $303.06 (95% upside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 28 | $155.18 |
0%
|
| 3-Year Average | 54.6 | $303.06 |
+95%
|
| 5-Year Average | 59.6 | $330.86 |
+113%
|
| Industry Average | 27.6 | $153.12 |
-1%
|
| Country Average | 22.9 | $126.91 |
-18%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
$28.5B
|
/ |
Feb 2026
$908.9m
|
= |
|
|
$28.5B
|
/ |
Jan 2027
$1.5B
|
= |
|
|
$28.5B
|
/ |
Jan 2028
$1.6B
|
= |
|
|
$28.5B
|
/ |
Jan 2029
$1.9B
|
= |
|
|
$28.5B
|
/ |
Jan 2030
$2.2B
|
= |
|
|
$28.5B
|
/ |
Jan 2031
$2.5B
|
= |
|
|
$28.5B
|
/ |
Jan 2032
$2.7B
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
25.9B USD | 28 | |
| JP |
|
Medical Data Vision Co Ltd
TSE:3902
|
37.9T JPY | 227.5 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 53.1 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14.1B AUD | 59.6 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 20.6 | |
| SE |
|
Sectra AB
STO:SECT B
|
49.6B SEK | 91.5 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.8B USD | 42.2 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD | 18.6 | |
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
267.3B INR | 40.3 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
18.9B CNY | -61.4 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | -328 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.3 |
| Median | 22.9 |
| 70th Percentile | 33.2 |
| Max | 1 826 183.3 |
Other Multiples
Veeva Systems Inc
Glance View
Veeva Systems Inc., born in the heart of Silicon Valley in 2007, embarked on its journey with a clear mission: to revolutionize the pharmaceutical and life sciences industries with cloud-based solutions. Founded by Peter Gassner, who previously held leadership roles at Salesforce and PeopleSoft, Veeva identified a niche opportunity amid the highly-regulated, complex landscape of healthcare. The company began by offering Customer Relationship Management (CRM) software tailored for the life sciences sector, allowing clients to stay compliant with industry regulations while efficiently managing relationships across the intricate healthcare network. Veeva’s CRM solutions gradually became instrumental for pharmaceutical and biotech companies in conducting their marketing, sales, and collaboration activities. As Veeva expanded, it diversified its portfolio by delving into other digital solutions, such as data management and analytics, content management, and regulatory and compliance software. Its Vault platform stood out, providing a unified suite for managing a vast array of business processes and content across powerful cloud applications. This approach enabled Veeva to serve its clientele throughout the drug development lifecycle, from research and development to commercialization. By adopting a subscription-based pricing model, Veeva ensured a steady revenue stream while continuously enhancing its offerings, solidifying its position as both a trusted partner and a critical component of its clients’ operational infrastructure. Through these strategic expansions, Veeva Systems Inc. not only adapted to the evolving demands of the healthcare sector but also reinforced its dominance in the specialized domain of life sciences cloud technology.